Back
Back
Back

Annual Conference Schedule

Please join Acella Pharmaceuticals for the following conferences and register to attend one of our product theaters highlighting NP Thyroid®.

June

Endocrine Society

June 11–14 - Atlanta, GA

Attendance: Hybrid (In-person / Online)

Product Theater

Monday, June 13 at 1:00-1:45 pm ET
with Dr. Thanh Hoang, DO, FACP

AANP

June 21–26 - Orlando, FL

Attendance: Hybrid (In-person / Online)

Product Theater

Wednesday, June 22 at 12:00-1:15 pm ET
with Mandy Cotten, APRN, FNP-C

Title

Hypothyroidism Uncovered: Thyroid Replacement
Options for You and Your Patients

July

MEDS West

July 13–16 - Newport Beach, CA

Attendance: Hybrid (In-person / Online)

Product Theater

Saturday, July 16 at 7:10-7:55 am PT
with Susan VanBeuge, DNP, FNP-BC, FAANP​

Title

Hypothyroidism Uncovered: Thyroid Replacement
Options for You and Your Patients

National Nurse Practitioner
Symposium

July 21–24 - Keystone, CO

Attendance: Hybrid (In-person / Online)

Product Theater

Thursday, July 21 at 11:30 am-1:00 pm MT
with Christine Kessler, MN, CNS, ANP, BC-ADM, CDTC, FAANP

Title

Hypothyroidism Uncovered: Thyroid Replacement
Options for You and Your Patients

August

Western Endocrine Association
(WEA)

Aug 26-28 - Sedona, AZ

Attendance: Hybrid (In-person / Online)

Booth TBD

September

Hormones & Beyond

September 15–18 - Albuquerque, NM

Attendance: Hybrid (In-person / Online)

Booth TBD

Family Medicine Experience

September 20–24 - Washington, DC

Attendance: Hybrid (In-person / Online)

Product Theater

Thursday, September 22 at 11:30 am-12:15 pm ET
with Robert Quarles, DO

Title

Hypothyroidism Uncovered: A Primary Care Perspective

Texas Nurse Practitioner
Conference

September 22–25 - Round Rock, TX

Attendance: In-person

Product Theater

Thursday, September 22 at 12:15-1:15 pm CT
with Angela Golden, DNP, FNP-C, FAANP

Title

Hypothyroidism Uncovered: Thyroid Replacement
Options for You and Your Patients

october

MEDS Fall

October 12–15 - Lake Buena Vista, FL

Attendance: Hybrid (In-person / Online)

Product Theater

Wednesday, October 12 at 8:00-8:45 am ET
with Christine Kessler, MN, CNS, ANP, BC-ADM, CDTC, FAANP

Title

Hypothyroidism Uncovered: Thyroid Replacement
Options for You and Your Patients

American Thyroid Association
Conference

October 19–23 - Montreal, Quebec, Canada

Attendance: In-person

Product Theater

October 21 at 11:00 am-12:00 pm ET
with Thanh Hoang, DO, FACP, FACE | David Robertson, MD | Elizabeth McAninch, MD

Title

Treating Hypothyroidism: A Patient Focused Discussion
on the Utility and Perception of Desiccated Thyroid Extract

AMMG

October 27–30 - Denver, CO

Attendance: In-person

Booth TBD

December

A4M

December 9–11 - Las Vegas, NV

Attendance: In-person

Booth TBD

INDICATIONS & IMPORTANT RISK INFORMATION INCLUDING BLACK BOX WARNING
Important Risk Information

Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
  • NP Thyroid® is contraindicated in patients with uncorrected adrenal insufficiency, untreated thyrotoxicosis, and hypersensitivity to any component of the product.
  • In the elderly and in patients with cardiovascular disease, NP Thyroid® should be used with greater caution than younger patients or those without cardiovascular disease.
  • Use of NP Thyroid® in patients with diabetes mellitus or adrenal cortical insufficiency may worsen the intensity of their symptoms.
  • The therapy of myxedema coma requires simultaneous administration of glucocorticoids.
  • Concomitant use of NP Thyroid® with oral anticoagulants alters the sensitivity of oral anticoagulants. Prothrombin time should be closely monitored in thyroid-treated patients on oral anticoagulants.
  • In infants, excessive doses of NP Thyroid® may produce craniosynostosis.
  • Partial loss of hair may be experienced by children in the first few months of therapy but is usually transient.
  • Adverse reactions associated with NP Thyroid® therapy are primarily those of hyperthyroidism due to therapeutic overdosage.
  • Many drugs and some laboratory tests may alter the therapeutic response to NP Thyroid®. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs. Administer at least 4 hours before or after drugs that are known to interfere with absorption. Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption.
  • NP Thyroid® should not be discontinued during pregnancy, and hypothyroidism diagnosed during pregnancy should be promptly treated.

Indication

NP Thyroid® (thyroid tablets, USP) is a prescription medicine that is used to treat a condition called hypothyroidism from any cause, except for cases of temporary hypothyroidism, which is usually associated with an inflammation of the thyroid (thyroiditis). It is meant to replace or supplement a hormone that is usually made by your thyroid gland.

NP Thyroid® is also used in the treatment and prevention of normal functioning thyroid goiters, such as thyroid nodules, Hashimoto’s thyroiditis, multinodular goiter, and in the management of thyroid cancer.